Coinbase shares tumble as muted crypto trading leads to a third-quarter miss

Coinbase shares tumble as muted crypto trading leads to a third-quarter miss


Monitors display Coinbase signage during the company’s initial public offering (IPO) at the Nasdaq MarketSite in New York, on Wednesday, April 14, 2021.

Michael Nagle | Bloomberg | Getty Images

 

Coinbase Wednesday reported weaker-than-expected third-quarter results, weighed down by muted trading in the cryptocurrency market.

The stock fell more than 4% in extended trading.

Here’s what the company reported for the third quarter compared with what Wall Street expected, according to a survey of analysts by LSEG:

  • Earnings per share: 28 cents vs. 41 cents expected
  • Revenue: $1.21 billion vs. $1.26 billion expected

Coinbase, which operates the largest U.S. marketplace for buying and selling cryptocurrencies, reported net income of $75.5 million, or 28 cents per share, compared with a year-ago loss of $2.3 million, or 1 cent a share.

Net income in the latest quarter included $121 million in pretax losses on Coinbase’s crypto investment portfolio, the vast majority of which were unrealized, as crypto prices were lower on Sept. 30 compared with June 30.

Within its core business, revenue from retail trading grew 98% to $483.3 million from the previous year, while institutional revenue brought in $55.3 million during the quarter, a 292% jump from the same period a year ago. Total transaction revenue was $572.5 million, a 98% increase year-over-year.

Revenue from Coinbase’s subscription and services – which includes stablecoins, staking and leverage for Prime traders among other things – saw a more modest decline of 7% to $556.1 million.

The cryptocurrency market has been in a bit of a slump for much of this year, stuck in a narrow range between $55,000 and $70,000. Bitcoin has been absent any significant catalysts and suffered low volatility as investors monitored the U.S. presidential race and largely stood on the sidelines. Coinbase has been an active lobbyist for the crypto industry this year, spending millions backing pro-crypto political action committees.

Stablecoins — widely believed to be crypto’s killer app — were a bright spot in the third quarter. While crypto price action has been tepid, the market cap for stablecoins reached new highs, helping push Coinbase’s third-quarter stablecoin revenue to $246.9 million. That’s an increase of 2% quarter-over-quarter but up 43% from the same period a year ago.

Coinbase has a 50/50 revenue sharing agreement with Circle for the interest income of the reserves backing USD Coin (USDC), the second largest dollar-backed stablecoin on the market. That revenue could be challenged in the current quarter with interest rates expected to continue coming down.

Coinbase also announced a $1 billion stock buyback in its earnings report.

This is a breaking news story. Check back for updates.

Don’t miss these cryptocurrency insights from CNBC PRO:



Source

Google joins Microsoft in telling users Anthropic is still available outside defense projects
World

Google joins Microsoft in telling users Anthropic is still available outside defense projects

Google CEO Sundar Pichai gestures to the crowd during Google’s annual I/O developers conference in Mountain View, California, on May 20, 2025. David Paul Morris | Bloomberg | Getty Images Google said it will continue offering Anthropic’s artificial intelligence technology for clients, excluding for defense work, a day after Microsoft issued a similar statement to […]

Read More
Market turmoil is hitting most traditional safe havens. UBS says this is the place to hide
World

Market turmoil is hitting most traditional safe havens. UBS says this is the place to hide

The U.S. and Israel are showing signs of escalating their war against Iran – a move that could batter a variety of assets, even traditional safe havens. To protect their portfolios, investors can snap up stocks from an oft-shorted sector: pharmaceuticals, UBS analysts say. Since the first strikes last Saturday, the Iran War has roiled […]

Read More
Zealand’s stock falls 35% after disappointing drug result. Its CEO tells CNBC people need to focus less on the ‘weight loss Olympics’
World

Zealand’s stock falls 35% after disappointing drug result. Its CEO tells CNBC people need to focus less on the ‘weight loss Olympics’

Wegovy is produced by pharmaceutical company Novo Nordisk and has been approved for specifically for chronic weight management in adults and adolescents. (Photo by Steve Christo – Corbis/Corbis via Getty Images) Steve Christo – Corbis | Corbis News | Getty Images The chief executive of drugmaker Zealand Pharma sought to calm investors about the latest […]

Read More